GlassScriptPhysician profile
Susan Longar
NPI 1578506960
$2,872.85
in general payments reported to CMS, 2019-2025
25 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $67.36 · 2021: $285 · 2022: $532 · 2023: $432 · 2024: $451 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $346.05 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $289.69 | 2022-2025 | Rocklatan, Tryptyr |
| Mallinckrodt Hospital Products INC. | $258.01 | 2021-2022 | |
| Oyster Point Pharma, INC. | $224.58 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $204.38 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $198.39 | 2019-2021 | |
| Allergan, INC. | $173.47 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $159.36 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $114.42 | 2024 | |
| Amgen INC. | $110.64 | 2024-2025 | Tepezza |
| Lumibird Medical INC. | $109.94 | 2025 | |
| Thea Pharma INC. | $101.42 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $94.77 | 2019-2023 | Cequa |
| Harrow Eye, LLC | $80.21 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $73.80 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.70 | 2021-2022 | |
| Dompe US, INC. | $44.31 | 2019-2025 | Oxervate |
| Horizon Therapeutics Plc | $40.40 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $33.77 | 2021-2022 | |
| Astellas Pharma US INC | $31.94 | 2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $26.49 | 2019 | |
| Merck Sharp & Dohme LLC | $24.85 | 2022 | |
| Sight Sciences, INC. | $23.62 | 2023 | Tearcare System |
| Akorn, INC. | $22.62 | 2019 | |
| Rxsight INC | $16.02 | 2023 | Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Longar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.